The drug discovery process aims to identify small molecule compounds that have potential as therapeutics for disease, by eliciting a desired effect from a biological target. With the industry striving for cost-effective and efficient approaches to the drug discovery process, screening technologies that enable the earlier identification of compounds most likely to make it to clinic are key.
This month, in our Drug Discovery Screening SelectScience Special Feature, we take a look at some of the latest trends in screening for drug discovery and the technologies advancing this field, including the latest methods for phenotypic screening, new tools for structure-based drug discovery, CRISPR screening technologies, and developments in data analysis. Plus, hear from the scientists hoping to bring effective treatments to patients faster.
Read on to learn about:
Sample preparation in metabolomics, NGS and cell and protein analysis, can be laborious, time-consuming, and have limited reproducibility. In this video interview from SLAS2019, learn how the Agilent Bravo automated liquid handling platform and comprehensive software can help you to automate sample preparation for consistent and reproducible results, improving downstream analysis and creating more walk-away time. Learn more about the Bravo liquid handling platform and watch the video interview to learn how the technology can help advance drug discovery.
Immune cell characterization requires a multitude of assays to identify different cell types and their function – immunophenotyping assays aid in identifying classic cell surface markers, while cytokine analysis assays are required for identifying the functional profile of those cells.
Running these assays separately is costly, time-consuming and complex. In this infographic from Sartorius, discover a T cell activation assay in which cell health, function, phenotype, and secreted cytokines were simultaneously analyzed in a single well on the Intellicyt iQue® Screener PLUS, using miniaturized assay volumes.
This application note describes how Dianthus by NanoTemper Technologies was used for molecular interaction screening of a fragment library from a large chemical space with target molecule histone methyltransferase (HMT) G9a, an epigenetic gene regulator and focus of oncological drug discovery.
Learn how the technology enables fast detection and quantification of molecular interactions in solution, independent of the mass and size of the two interacting molecules utilizing very little sample.
Cryo-electron microscopy (cryo-EM) enables high-resolution imaging of large protein complexes without crystallization, helping you to visualize even the most challenging targets, such as GPCRs or multi-component complexes.
In this download, from Thermo Fisher Scientific, learn more about the power of cryo-EM and how it can help you to unlock new biological insights and speed up your drug discovery projects.
In this exclusive interview for The Scientists’ Channel, watch Dr. Richard Henderson, 2017 Nobel Prize winner in chemistry, discuss the growing importance of cryo-electron microscopy for science and how leading pharmaceutical companies are working together to utilize this revolutionary technique.
With the industry striving for more physiologically relevant testing conditions to improve predictability in drug discovery, we speak to Dr. Ryan Gordon, of StemoniX, to learn about the company’s microBrain 3D platform.
Dr. Nathalie Maubon launched HCS Pharma in 2014, inspired by an idea: in order to obtain and select effective drugs, more relevant cellular models are needed for screening. In this SelectScience interview, Maubon provides insight into the development of in vitro models and assays to advance phenotypic screening, the cellular imaging technology enabling her work, and why microenvironment is key to the future of drug discovery.
3D screening provides rich data, essential for faster drug discovery. Learn about the power of true 3D image analysis and how it is helping to advance immune-oncology research in this interview with scientists from contract research organization OcellO. Plus, discover the new technology from Olympus enabling true 3D high-content analysis in our recent webinar.
From novel target discovery to target validation and better identification of compound mechanisms of action, genomic editing has potential to impact many applications in drug discovery. Learn how CRISPR-Cas9 technology is opening up new applications of genomic screening, including whole-genome studies, in this interview with Dr. James Goldmeyer of Horizon Discovery. Plus learn how the technology is playing a key role in studies at the Duke University Functional Genomics Shared Resource in this interview with its director, Dr. So Young Kim.
In a recent video interview, Dr. Jonathan Wingfield , Principal Scientist at AstraZeneca, discusses the development of acoustic mass spectrometry technology for high-throughput screening and how the technology is helping to save time and the reagent costs associated with screening millions of compounds.
Hear how scientists at GlaxoSmithKline (GSK), Stevenage, UK, are working in collaboration with TTP Labtech to develop new liquid handling technology that will help to accelerate screening assay development, from target identification, to candidate molecule identification.
Explore our selection of the biggest news stories in drug discovery screening:
Discover leading scientists on video: